INDIANAPOLIS — Eli Lilly and Co. has announced the completion of the acquisition of Novartis Animal Health. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
As part of the approval, certain animal health assets in the U.S. relating to the Sentinel® canine parasiticide franchise will be divested to Virbac, as has been previously announced. All other closing conditions have also been met.
The combined organization will increase Elanco's product portfolio, expand its global commercial presence and deliver more innovation to customers. The acquisition also augments Elanco's manufacturing and. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
